A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis (Q57392733)

From Wikidata

Jump to navigation Jump to search

article by Jaya Chakravarty et al published April 2011 in Vaccine

Language	Label	Description	Also known as
English	A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis	article by Jaya Chakravarty et al published April 2011 in Vaccine

Statements

scholarly article

0 references

A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis (English)

0 references

visceral leishmaniasis

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Karen D Cowgill

object named as

Karen D. Cowgill

11

0 references

13

object named as

Shyam Sundar

0 references

12

object named as

Steven G. Reed

0 references

8

object named as

Rhea N. Coler

0 references

author name string

Jaya Chakravarty

1

0 references

Subodh Kumar

2

0 references

Sonali Trivedi

3

0 references

Vijay K. Rai

4

0 references

Anup Singh

5

0 references

Jill A. Ashman

6

0 references

Elsa M. Laughlin

7

0 references

Stuart J. Kahn

9

0 references

Anna Marie Beckmann

10

0 references

Franco M. Piazza

14

0 references

language of work or name

0 references

publication date

April 2011

0 references

0 references

29

0 references

19

0 references

3531-3537

0 references

Leishmaniasis and poverty

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

Leishmaniasis: current situation and new perspectives

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

The burden of visceral leishmaniasis in South Asia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

Leishmaniasis: current treatment and prospects for new drugs and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

The economic impact of visceral leishmaniasis on rural households in one endemic district of Bihar, India

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

Household cost-of-illness of visceral leishmaniasis in Bihar, India

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

Management of visceral leishmaniasis in rural primary health care services in Bihar, India

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

Taking toll: lipid A mimetics as adjuvants and immunomodulators

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

Development of a leishmaniasis vaccine: the importance of MPL.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

Safety and immunogenicity of a defined vaccine for the prevention of cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with meglumine antimoniate for the treatment of cutaneous leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

Molecular characterization of a kinesin-related antigen of Leishmania chagasi that detects specific antibody in African and American visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

The epidemiology of Leishmania donovani infection in high transmission foci in India.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

Visceral leishmaniasis in southeastern Nepal: a cross-sectional survey on Leishmania donovani infection and its risk factors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

Longitudinal seroepidemiologic study of visceral leishmaniasis in hyperendemic regions of Bihar, India.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

Risk factors for kala-azar in Bangladesh

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

Immunity in kala-azar

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

Visceral leishmaniasis: new health tools are needed

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.02.096

7 January 2021

Identifiers

10.1016/J.VACCINE.2011.02.096

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57392733&oldid=1997543844"